Accessibility Menu
 
Larimar Therapeutics logo

Larimar Therapeutics

(NASDAQ) LRMR

Current Price$3.35
Market Cap$372.80M
Since IPO (2020)-71%
5 Year-73%
1 Year+91%
1 Month-26%

Larimar Therapeutics Financials at a Glance

Market Cap

$372.80M

Revenue (TTM)

$0.00

Net Income (TTM)

$166.00M

EPS (TTM)

$-2.08

P/E Ratio

-1.62

Dividend

$0.00

Beta (Volatility)

1.11 (Average)

Price

$3.35

Volume

47,279

Open

$3.59

Previous Close

$3.58

Daily Range

$3.31 - $3.65

52-Week Range

$1.80 - $6.42

LRMR News

LRMR: Motley Fool Moneyball Superscore

63

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Larimar Therapeutics

Industry

Biotechnology

Employees

71

CEO

Carole S. Ben-Maimon, MD

Headquarters

Bala Cynwyd, PA 19004, US

LRMR Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-110%

Return on Capital

-1%

Return on Assets

-80%

Earnings Yield

-61.73%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$372.80M

Shares Outstanding

104.13M

Volume

47.28K

Avg. Volume

4.36M

Financials (TTM)

Gross Profit

$0.00

Operating Income

$172.50M

EBITDA

$172.15M

Operating Cash Flow

$113.20M

Capital Expenditure

$91.00K

Free Cash Flow

$113.29M

Cash & ST Invst.

$136.85M

Total Debt

$4.07M

Larimar Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$372.80M

N/A

Market Cap/Employee

$5.74M

N/A

Employees

65

N/A

Net Income

$29.61M

-1.1%

EBITDA

$31.12M

-0.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Net Cash

$196.61M

+28.8%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$2.72M

-27.8%

Short Term Debt

$1.06M

-3.5%

Return on Assets

-79.61%

N/A

Return on Invested Capital

-1.07%

N/A

Free Cash Flow

$44.61M

-67.8%

Operating Cash Flow

$44.61M

-68.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KYTXKyverna Therapeutics, Inc.
$8.59-9.48%
LXEOLexeo Therapeutics, Inc. Common Stock
$4.81-5.50%
AMRNAmarin Corporation plc
$14.21-2.40%
DBVTDBV Technologies S.A.
$18.94-3.60%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$14.27-0.05%
TET1 Energy Inc.
$6.62+0.17%
POETPoet Technologies
$14.27-0.11%
FFord Motor Company
$13.20-0.01%

Questions About LRMR

What is the current price of Larimar Therapeutics?

Larimar Therapeutics is trading at $3.35 per share.

What is the 52-week range for Larimar Therapeutics?

Over the past 52 weeks, Larimar Therapeutics has traded between $1.80 and $6.42.

How much debt does Larimar Therapeutics have?

As of the most recent reporting period, Larimar Therapeutics reported total debt of $3.78M.

How much cash does Larimar Therapeutics have on hand?

Larimar Therapeutics reported $177.91M in cash and cash equivalents in its most recent financial results.

What is Larimar Therapeutics’s dividend yield?

Larimar Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.